Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Moderna, Inc. - Common Stock
(NQ:
MRNA
)
41.01
+0.14 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Moderna to Present at Upcoming Conferences in September 2025
August 21, 2025
Via
ACCESS Newswire
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 01, 2025
Via
ACCESS Newswire
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
August 01, 2025
Via
ACCESS Newswire
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
July 30, 2025
Via
ACCESS Newswire
Moderna Announces Data to be Presented at ESMO Congress 2025
July 28, 2025
Via
ACCESS Newswire
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
May 31, 2025
Via
ACCESS Newswire
Moderna Announces Update on Investigational Pandemic Influenza Program
May 28, 2025
Via
ACCESS Newswire
Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
February 28, 2025
Via
ACCESS Newswire
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
July 25, 2025
Via
ACCESS Newswire
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
June 30, 2025
Via
ACCESS Newswire
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
June 12, 2025
Via
ACCESS Newswire
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
June 11, 2025
Via
ACCESS Newswire
Moderna to Present at Upcoming Conferences in June 2025
May 27, 2025
Via
ACCESS Newswire
Moderna to Present at Upcoming Conferences in March 2025
February 25, 2025
Via
ACCESS Newswire
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
January 24, 2025
Via
ACCESS Newswire
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
Via
ACCESSWIRE
Moderna to Present at Upcoming Conferences in December 2024
November 25, 2024
Via
ACCESSWIRE
Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine
May 23, 2025
Via
ACCESS Newswire
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
May 21, 2025
Via
ACCESS Newswire
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
May 08, 2025
Via
ACCESS Newswire
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
May 01, 2025
Via
ACCESS Newswire
Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
April 10, 2025
Via
ACCESS Newswire
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
November 08, 2024
Via
ACCESSWIRE
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 07, 2024
Via
ACCESSWIRE
Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025
April 07, 2025
Via
ACCESS Newswire
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
March 31, 2025
Via
ACCESS Newswire
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
February 14, 2025
Via
ACCESS Newswire
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
January 29, 2025
Via
ACCESS Newswire
Moderna Announces Updates on Pandemic Influenza Program
January 17, 2025
Via
ACCESS Newswire
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
November 12, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today